Patents by Inventor Alain Laurent

Alain Laurent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210009989
    Abstract: A method for extracting nucleic acids using suitable solid supports, for example silica-based. In particular, the method includes a step of capturing nucleic acids by placing the sample in contact with a suitable solid support, characterized in that, prior to the capture step, said method includes a step of treating the sample with at least one reagent for masking the amine or carboxylic acid functional groups of the proteins and/or polysaccharides of the sample.
    Type: Application
    Filed: March 15, 2019
    Publication date: January 14, 2021
    Applicant: BIOMÉRIEUX
    Inventors: Alain LAURENT, Arnaud BURR, Ali LAAYOUN
  • Publication number: 20200385369
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, and its use in therapy.
    Type: Application
    Filed: January 8, 2020
    Publication date: December 10, 2020
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Patent number: 10752892
    Abstract: A three-layer complex including at least one magnetic compound, at least one inorganic silicate and at least one compound having an affinity for the at least one magnetic compound and/or the at least one inorganic silicate. The three-layer complex, and associated methods, may be applicable in the field of in vitro diagnostics.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: August 25, 2020
    Assignee: BIOMERIEUX
    Inventors: Arnaud Burr, Ali Laayoun, Alain Laurent, Raphäel Veyret
  • Patent number: 10752615
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 25, 2020
    Assignee: GB005, Inc.
    Inventors: Alain Laurent, Stephen J. Morris
  • Publication number: 20200247808
    Abstract: Compounds having the Formula (I), and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (Formula I)) are useful as kinase inhibitors or modulators, including BTK modulation or inhibition, wherein X1, X2, m, m?, E and R1 are as defined herein.
    Type: Application
    Filed: September 9, 2016
    Publication date: August 6, 2020
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Publication number: 20200215036
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly RLK (TXK). The present invention is directed to a compound of Formula (I) or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Application
    Filed: August 21, 2018
    Publication date: July 9, 2020
    Inventors: Alain Laurent, Stephen J. Morris
  • Patent number: 10680826
    Abstract: There is provided a method and system for authenticating a production of products. The method and system comprise determining if configuration data for the production run is authorized and, if the production run is authorized, generating a security token and associating the token with configuration data. The configuration data is digitally signed by generating a digital signature and associating the digital signature with the configuration data. The digital signature associated with the digitally signed configuration data is verified. Products are then produced in a production run according to the digitally signed configuration data, and the set of secure product identifiers is printed on the products according to the digitally signed configuration data.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 9, 2020
    Assignee: INEXTO SA
    Inventors: Alain Laurent Robert Borlet-Hote, Erwan Fradet, Yannick Georges Charles Gauthier
  • Patent number: 10562893
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: February 18, 2020
    Assignee: GB005, INC.
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Publication number: 20190375763
    Abstract: The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.
    Type: Application
    Filed: July 13, 2017
    Publication date: December 12, 2019
    Applicants: BIOMÉRIEUX, UNIVERSITÉ DE CAEN NORMANDIE
    Inventors: Sylvain URSUEGUI, Alain LAURENT, Ali LAAYOUN, Frédéric FABIS
  • Publication number: 20190263790
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Application
    Filed: August 16, 2017
    Publication date: August 29, 2019
    Inventors: Alain Laurent, Stephen J. Morris
  • Publication number: 20190112329
    Abstract: A method of functionalizing RNA in a liquid sample includes reacting an anhydride function of a binding molecule with at least one RNA molecule at one or more hydroxyl groups in any of position 2? of a ribose of any nucleotide of the RNA molecule, position 2? of the ribose of the terminal nucleotide at the 3? end of the RNA molecule, or position 3? of the ribose of the terminal nucleotide at the 3? end of the RNA molecule, to obtain functionalized RNA. The binding molecule includes an aza-isatoic anhydride or derivative thereof linked to a group of interest by a linkage, and an aza-anthranilate is formed from reacting the anhydride function of the binding molecule with a hydroxyl group of the RNA molecule so as to join the RNA molecule to the group of interest. The group of interest is a marker, labelling precursor, or ligand.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: BIOMERIEUX
    Inventors: Thomas CAILLY, Frédéric FABIS, Ali LAAYOUN, Alain LAURENT, Sylvain URSUEGUI
  • Patent number: 10174068
    Abstract: The present invention relates to a method of functionalization of at least one ribonucleic acid (RNA) molecule, contained in a liquid sample, which includes the following steps: a) providing at least: one binding molecule consisting of an aza-isatoic anhydride or a derivative thereof, one group of interest, and one linkage joining the binding molecule to the group of interest, b) reacting the anhydride function of the binding molecule with at least one hydroxyl group carried: in position 2? of the ribose of one of the RNA nucleotides, and/or in position(s) 2? and/or 3? of the ribose of the nucleotide at the terminal 3? end of the RNA, and obtaining an aza-anthranilate that joins, by means of the linkage, the RNA to the group of interest.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 8, 2019
    Assignee: BIOMERIEUX
    Inventors: Thomas Cailly, Frédéric Fabis, Ali Laayoun, Alain Laurent, Sylvain Ursuegui
  • Publication number: 20180319781
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.
    Type: Application
    Filed: September 22, 2016
    Publication date: November 8, 2018
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Publication number: 20180179210
    Abstract: The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 28, 2018
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Publication number: 20180034640
    Abstract: There is provided a method and system for authenticating a production of products. The method and system comprise determining if configuration data for the production run is authorized and, if the production run is authorized, generating a security token and associating the token with configuration data. The configuration data is digitally signed by generating a digital signature and associating the digital signature with the configuration data. The digital signature associated with the digitally signed configuration data is verified. Products are then produced in a production run according to the digitally signed configuration data, and the set of secure product identifiers is printed on the products according to the digitally signed configuration data.
    Type: Application
    Filed: January 29, 2016
    Publication date: February 1, 2018
    Applicant: INEXTO SA
    Inventors: Alain Laurent Robert BORLET-HOTE, Erwan FRADET, Yannick Georges Charles GAUTHIER
  • Publication number: 20170342400
    Abstract: A three-layer complex including at least one magnetic compound, at least one inorganic silicate and at least one compound having an affinity for the at least one magnetic compound and/or the at least one inorganic silicate. The three-layer complex, and associated methods, may be applicable in the field of in vitro diagnostics.
    Type: Application
    Filed: December 21, 2015
    Publication date: November 30, 2017
    Applicant: BIOMÉRIEUX
    Inventors: Arnaud BURR, Ali LAAYOUN, Alain LAURENT, Raphäel VEYRET
  • Patent number: 9822120
    Abstract: The present invention relates to a novel family of protein kinase inhibitors of Formula I: as well as to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 21, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9795608
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9796716
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
  • Publication number: 20170158697
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 8, 2017
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose